da Luz, Felipe Q. http://orcid.org/0000-0002-2088-4099
Sainsbury, Amanda http://orcid.org/0000-0001-9176-1574
Salis, Zubeyir http://orcid.org/0000-0003-2982-4591
Hay, Phillipa
Cordás, Táki
Morin, Charles M. http://orcid.org/0000-0002-8649-8895
Paulos-Guarnieri, Léo http://orcid.org/0000-0003-3269-7941
Pascoareli, Luisa http://orcid.org/0000-0003-0140-6507
El Rafihi-Ferreira, Renatha http://orcid.org/0000-0002-2212-4608
Article History
Received: 9 March 2022
Revised: 14 December 2022
Accepted: 16 December 2022
First Online: 29 December 2022
Competing interests
: AS and ZS own 50% each of the shares in Zuman International, a company which receives royalties and other payments for educational resources and services about adult weight management and research methodology. AS has also received presentation fees and travel reimbursements from Eli Lilly and Co, the Pharmacy Guild of Australia, Novo Nordisk, the Dietitians Association of Australia, Shoalhaven Family Medical Centres, the Pharmaceutical Society of Australia, and Metagenics, and served on the Nestlé Health Science Optifast VLCD advisory board from 2016 to 2018. PH receives/has received sessional fees and lecture fees from the Australian Medical Council, Therapeutic Guidelines publication, and HETI New South Wales Institute of Psychiatry and royalties/honoraria from Hogrefe and Huber, McGraw Hill Education, and Blackwell Scientific Publications, Biomed Central and PlosMedicine and she has received research grants from the NHMRC and ARC. She is Chair of the National Eating Disorders Collaboration Steering Committee in Australia (2012-) and was Member of the ICD-11 Working Group for Eating Disorders (2012–2019) and was Chair Clinical Practice Guidelines Project Working Group (Eating Disorders) of RANZCP (2012–2015). She has prepared a report under contract for Shire Pharmaceuticals in regard to Binge Eating Disorder (July 2017) and consulting fees for education of doctors from Takeda Pharmaceuticals. All views in this paper are her own. CM has research contracts with Eisai, Idorsia, Lallemand Health Consulting, and is an advisor for Eisai, Idorsia, Pear Therapeutics, and Sunovion.